Study finds smoking impairs the bioenergetic immune response to Mtb infection
Smoking and tuberculosis (TB) have always had a strong epidemiological association. Smokers’ alveolar macrophages (AM) have demonstrated significant immune defects following infection; however, recently, macrophage glycolytic reprogramming has become the early host immune response to mycobacterium tuberculosis (Mtb) infection, according to researchers.
A recent
study
aimed to compare baseline metabolic characteristic and the
glycolytic response with infection of human AM from smokers and
nonsmokers. The researchers obtained AM at bronchoscopy and
extracellular flux analyses were conducted to establish baseline
metabolic characteristics compared with human monocyte derived
macrophages (MDM).
“We hypothesized, therefore,
that smokers’ AM would demonstrate an attenuated metabolic
response to infection, in line with the attenuated cytokine
response observed in these cells. To address this, metabolic
interrogation of smokers’ and nonsmokers’ AM was
performed using extracellular flux analyses,” the authors
wrote. “Our data reveal significant differences in terms
of baseline metabolic activity and metabolic reserves, with
smokers’ AM ultimately demonstrating an impaired metabolic
response to infection that may contribute to increased
susceptibility to infection observed in this
population.”
Also, differences in glycolytic
response were measured by extracellular flux analysis, gene
expression analyses, and correlated with production of the
glycolysis-driven IL-1β and PGE2. There were
similar tests conducted in cigarette smoke extract (CSE)-treated
MDM, representing the alternative model.
The results
revealed that at baseline, human AM from nonsmokers typically
have a significantly lower extracellular acidification rate
(ECAR)/oxygen consumption rate (OCR) ratio than MDM, however,
they retain substantial glycolytic reserve. When compared with
nonsmokers, smokers’ AM have reduced metabolic activity,
reduced glycolytic reserve, and reduced respiratory capacity.
“Human
AM demonstrate metabolic plasticity that allows glycolytic
reprogramming to occur following Mtb infection,” the
authors wrote. “In smokers, this metabolic reserve is
significantly attenuated, with consequent impairment of the
glycolytic response to infection.”
After
infection with Mtb, smokers’ AM were found to have
significantly reduced glycolytic response. CSE-treated MDM also
demonstrated reduced metabolic activity and reserves, as well as
impaired glycolytic response to infection.
“The
impact of cigarette smoke on cell metabolism and function is
likely broad and complex, but with recent evidence for the
critical role of immunometabolism in the innate host defense
mechanisms, this work demonstrates fundamental defects in the AM
glycolytic response to infection following smoke
exposure,” concluded the authors. “As our
understanding of this relatively new field grows, host-directed
therapies to enhance early glycolytic reprogramming may
specifically benefit the smoking population.”
Source:
AJMC